An interventional study of Liposomal Ozonated Oil Ophthalmic Gel in Dry Eye Disease (DED), sponsored by University of Seville. Completed at 1 site in Spain. Open to female participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by University of Seville · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies in Dry Eye Syndromes with a site in Spain — 3 open to participants now, 4 under way, none of them phase 3. Dry Eye Syndromes · Spain.
Among the 44 studies in Dry Eye Syndromes with a site in Spain, this one is the 34th largest by enrollment of the 41 interventional ones that give a count, is one of 4 that started in 2025, is one of 21 with no phase, and was the 44th registered.
1,370 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.
Browse Dry Eye Syndromes studies →3 of the 44 studies in Dry Eye Syndromes with a site in Spain are open now. Recruiting first, the newest first:
Barbara Burgos Blasco · Sites in Spain
Ages 18+
Laboratorios Thea, Spain · Sites in Spain
Ages 18+
NOXELIS · Sites in Spain
Ages 18–78
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 65 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 8 · Phase 3 8 · Phase 4 5
First in 2009; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 27 is below the median of 60 across 1,132 interventional studies indexed under Dry Eye Syndromes.
Median enrollment 60 across the 41 interventional studies, 314 across the 3 observational. Of the 37 that completed or were terminated, 5 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 44 have an industry lead sponsor. The 10 most frequent:
University of Seville is the lead sponsor of 131 studies on the registry; 39 are open to participants now.
University of Seville has 8 studies filed under Dry Eye Syndromes — fewer than ten, so there is no comparison to draw.
2 of the studies in Dry Eye Syndromes with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06928142Otsuka Pharmaceutical Development & Commercialization, Inc.A Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Participants With Sjögren's | 2027-03-13 |
| NCT07715266NOXELISPOST CATARACT SURGERY DRY EYE DISEASE | 2027-05 |
Add all 2 to your calendar (.ics) → With an account.
Among the 44 studies in Dry Eye Syndromes with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study examines the effects of an eye gel containing liposomal ozonated oil in middle-aged women with dry eye disease. Dry eye can cause discomfort, an unstable tear film, and inflammation of the eye surface.
The main questions are whether one week of treatment changes:
Tear film stability and other signs and symptoms of dry eye.
Markers of inflammation in cells collected from the eye surface.
Proteins involved in maintaining connections between eye surface cells.
Women with dry eye use the eye gel for one week and undergo assessments before and after treatment. These assessments include a symptom questionnaire, eye surface examinations, and collection of small samples of cells from the conjunctiva, the thin tissue covering the white of the eye.
A separate group of healthy young women undergoes one assessment without receiving treatment. Their measurements provide reference values for comparison with those of women with dry eye.
This prospective, nonrandomized interventional study combines a before-and-after treatment assessment in women with dry eye disease with a separate healthy reference group.
Women aged 45-65 years with dry eye disease receive a commercially available ophthalmic gel containing liposomal ozonated oil, hydroxyethylcellulose, and poloxamer 407 for one week. Clinical assessments and conjunctival impression cytology are performed at baseline and after treatment. Healthy women aged 18-30 years undergo a single assessment without treatment.
Conjunctival samples are examined using quantitative real-time PCR to assess the expression of inflammatory cytokines, matrix metalloproteinases, and MUC5AC. Immunofluorescence analysis of ZO-1 and E-cadherin is used to examine epithelial junctional organization and cell morphology.
Treatment-associated changes are assessed within the dry eye group. The healthy group provides a biological reference and does not serve as a randomized treatment comparator.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Dry Eye Disease Group:
Healthy Reference Group:
Exclusion Criteria for Both Groups:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Women aged 45-65 years with dry eye disease receive liposomal ozonated oil ophthalmic gel for one week. Clinical ocular surface assessments and conjunctival impression cytology are performed before and after treatment.
Device: Liposomal Ozonated Oil Ophthalmic Gel
Healthy women aged 18-30 years without dry eye disease receive no study treatment and undergo a single clinical ocular surface assessment and conjunctival impression cytology. This group provides biological reference values.
Topical ophthalmic administration of a sterile gel containing liposomal ozonated oil, hydroxyethylcellulose, and poloxamer 407 (OZONEST Gel-K). Participants instill one drop into each eye three times daily for seven consecutive days.
Change From Baseline in First Non-Invasive Tear Break-Up Time
Change in first non-invasive tear break-up time (F-NIBUT), measured in seconds using an ocular surface analyzer, in participants with dry eye disease. F-NIBUT is the time between a complete blink and the first detected disruption of the tear film. Longer values indicate greater tear film stability.
Time frame: Baseline and Day 7
Change From Baseline in Conjunctival IL1B mRNA Expression
Change from baseline to Day 7 in relative IL1B mRNA expression in bulbar conjunctival cells collected by impression cytology from participants with dry eye disease. Expression is measured by quantitative real-time PCR, normalized to beta-actin, and calculated using the comparative Ct method. Results are expressed in relative units.
Time frame: Baseline and Day 7
Change From Baseline in Conjunctival IL6 mRNA Expression
Change from baseline to Day 7 in relative IL6 mRNA expression in bulbar conjunctival cells collected by impression cytology from participants with dry eye disease. Expression is measured by quantitative real-time PCR, normalized to beta-actin, and calculated using the comparative Ct method. Results are expressed in relative units.
Time frame: Baseline and Day 7
Change From Baseline in Conjunctival IL10 mRNA Expression
Change from baseline to Day 7 in relative IL10 mRNA expression in bulbar conjunctival cells collected by impression cytology from participants with dry eye disease. Expression is measured by quantitative real-time PCR, normalized to beta-actin, and calculated using the comparative Ct method. Results are expressed in relative units.
Time frame: Baseline and Day 7
Change From Baseline in Conjunctival TNF mRNA Expression
Change from baseline to Day 7 in relative TNF mRNA expression in bulbar conjunctival cells collected by impression cytology from participants with dry eye disease. Expression is measured by quantitative real-time PCR, normalized to beta-actin, and calculated using the comparative Ct method. Results are expressed in relative units.
Time frame: Baseline and Day 7
Change From Baseline in Conjunctival MMP1 mRNA Expression
Change from baseline to Day 7 in relative MMP1 mRNA expression in bulbar conjunctival cells collected by impression cytology from participants with dry eye disease. Expression is measured by quantitative real-time PCR, normalized to beta-actin, and calculated using the comparative Ct method. Results are expressed in relative units.
Time frame: Baseline and Day 7
Change From Baseline in Conjunctival MMP3 mRNA Expression
Change from baseline to Day 7 in relative MMP3 mRNA expression in bulbar conjunctival cells collected by impression cytology from participants with dry eye disease. Expression is measured by quantitative real-time PCR, normalized to beta-actin, and calculated using the comparative Ct method. Results are expressed in relative units.
Time frame: Baseline and Day 7
Change From Baseline in Conjunctival MMP9 mRNA Expression
Change from baseline to Day 7 in relative MMP9 mRNA expression in bulbar conjunctival cells collected by impression cytology from participants with dry eye disease. Expression is measured by quantitative real-time PCR, normalized to beta-actin, and calculated using the comparative Ct method. Results are expressed in relative units.
Time frame: Baseline and Day 7
Change From Baseline in Conjunctival MUC5AC mRNA Expression
Change from baseline to Day 7 in relative MUC5AC mRNA expression in bulbar conjunctival cells collected by impression cytology from participants with dry eye disease. Expression is measured by quantitative real-time PCR, normalized to beta-actin, and calculated using the comparative Ct method. Results are expressed in relative units.
Time frame: Baseline and Day 7
Plan to share: No — Individual participant data will not be shared.
No publications or documents are linked to this record.
Ran from Apr 2025 to primary completion in Sep 2026, 17 months.
Of 200 non-industry interventional studies with no phase under Dry Eye Syndromes, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 25. This study's 17 months is above that.
Counting every sponsor, half of 315 studies reached it within 10 months; a quarter within 4 and three quarters within 18.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.